mercredi 6 avril 2016

Business Briefing: F.D.A. Clears Cheaper Version of Johnson & Johnson Biologic

Federal officials have approved a cheaper version of Johnson & Johnson’s blockbuster drug Remicade, a biotech medicine for inflammatory diseases.











from NYT > Health http://ift.tt/1RYeSJX
via health&fitness

Aucun commentaire:

Enregistrer un commentaire